Headache News and Research

Latest Headache News and Research

New findings from Micromet's blinatumomab phase 1 trial on DLBCL

New findings from a phase 1 trial presented yesterday at the 53rd Annual American Society of Hematology (ASH) Annual Meeting demonstrate Micromet's blinatumomab induces durable responses in patients with extensively pre-treated diffuse large B cell lymphoma.

12 Dec 2011

Girls suffer more frequently from chronic pain than boys

Children who suffer from persistent or recurring chronic pain may miss school, withdraw from social activities, and are at risk of developing internalizing symptoms such as anxiety, in response to their pain. In the first comprehensive review of chronic pain in children and adolescents in 20 years, a group of researchers found that more children now are suffering from chronic pain and that girls suffer more frequently from chronic pain than boys.

9 Dec 2011

Positive results from Genentech's pertuzumab plus Herceptin Phase III study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced results from CLEOPATRA, the first randomized Phase III study of the investigational HER2-targeted medicine pertuzumab.

8 Dec 2011

Updated data from Novartis Afinitor plus everolimus Phase III study on advanced breast cancer

Updated results of a Phase III study of Afinitor (everolimus) tablets plus exemestane, a hormonal therapy, show everolimus provided additional time women with advanced breast cancer lived without their disease progressing.

8 Dec 2011

Headache affects one of every two HIV/AIDS patients

A University of Mississippi study of headaches among HIV patients is being hailed as a critical step to improving treatment and reducing unnecessary medical costs among sufferers.

7 Dec 2011

Health Alliance, Bayer sign outcomes-based contract to support MS patients

Bayer HealthCare and Health Alliance Medical Plans have entered into an outcomes-based contract for people with relapsing-remitting multiple sclerosis (MS) who are taking Betaseron (interferon beta-1b) to reduce the frequency of clinical exacerbations.

7 Dec 2011

FDA modifies requirements of Amgen's Nplate REMS Program

Amgen today announced the U.S. Food and Drug Administration (FDA) has modified the requirements of the Nplate (romiplostim) Risk Evaluation and Mitigation Strategy (REMS) Program.

7 Dec 2011

Headaches after TBI more prevalent among adolescents, girls

More than half a million children in the U.S. sustain a traumatic brain injury (TBI) every year. Adults who suffer TBI often report headaches afterward, but little is known about how often children suffer headaches after similar injuries. In a significant new study, "Headache After Pediatric Traumatic Brain Injury: A Cohort Study," researchers analyzed the prevalence of headaches three and 12 months after mild, moderate or severe TBI in children ages 5 to 17, and discovered the risk of headache was higher in adolescents (ages 13 to 17) and in girls.

6 Dec 2011

EnVivo presents positive EVP-6124 Phase 2b trial data on schizophrenia at 50th ACNP meeting

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it is presenting the comprehensive analysis of a recently completed Phase 2b clinical trial of EVP-6124, a novel, orally bioavailable nicotinic alpha-7 agonist, in schizophrenia at the American College of Neuropsychopharmacology 50th Anniversary Annual Meeting.

5 Dec 2011

Converting patients to lamotrigine extended-release for epilepsy treatment found effective and safe

Epilepsy drug-switching study shows that using more ethical control groups could be the way forward for testing both drug efficacy and safety

5 Dec 2011

Study: 3D-TV may cause seizures in children and adolescents

Certain visual patterns and flashing images can provoke seizures in susceptible individuals, particularly among children and adolescents. Some media reports on the recent introduction of 3D-television sets suggest that this new technology may cause seizures in some viewers.

5 Dec 2011

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis Pharmaceuticals Corporation will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases.

3 Dec 2011

Baby boomers more likely to develop HCV

Experts at Montefiore Medical Center urge the general public to be tested for the Hepatitis C virus, especially baby boomers, adults born between 1946-1964, who could be most at risk for this disease. Baby boomers are more likely to have been exposed to dangerous risk factors decades ago, such as sharing a drug needle, being tattooed or pierced with unsterilized tools or receiving a tainted blood transfusion.

2 Dec 2011

Einstein, Montefiore receive NINDS grant to establish clinical site for NeuroNEXT

In a development that could pave the way for treatment for rare neurological diseases and clues to more common ones, physician-scientists at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center, the University Hospital for Einstein, have secured a grant to establish a clinical site for the Network for Excellence in Neuroscience Clinical Trials.

2 Dec 2011

ACGME approves Cedars-Sinai's neurology residency training program

The Accreditation Council for Graduate Medical Education has approved a neurology residency training program at Cedars-Sinai Medical Center. Recruitment of the first group of three residents is under way through the 2012 "match," a process in which an independent organization pairs applicants with programs to meet the preferences of each.

30 Nov 2011

Genentech announces results from pertuzumab studies on HER2-positive breast cancer

Genentech, a member of the Roche Group, today announced the company will present results from studies of its investigational medicine pertuzumab in HER2-positive breast cancer at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium December 6-10.

30 Nov 2011

EC extends therapeutic indication for Soliris to treat atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the European Commission (EC) has extended the therapeutic indication for Soliris® (eculizumab) to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS).

29 Nov 2011

Post traumatic stress disorder and concussion syndrome treatable three years after injury: Study

Research led by Dr. Paul Harch, Associate Clinical Professor of Medicine at LSU Health Sciences Center New Orleans, has found that treatment with hyperbaric oxygen nearly three years after injury significantly improved function and quality of life for veterans with traumatic brain injury and post-traumatic stress disorder.

29 Nov 2011

Suppressing mosquitoes - the only way of controlling dengue

There is no vaccine against dengue, an emerging tropical disease regularly also hitting tourists, so the only way of controlling it is by suppressing the mosquitoes transmitting the disease.

28 Nov 2011

Migraines and depression risk: Study finds link

According to a new Canadian study, people who get attacks of migraine may be at a higher risk for developing clinical depression.

27 Nov 2011

Headache News and Research

Latest Headache News and Research

New findings from Micromet's blinatumomab phase 1 trial on DLBCL

Girls suffer more frequently from chronic pain than boys

Positive results from Genentech's pertuzumab plus Herceptin Phase III study on HER2-positive mBC

Updated data from Novartis Afinitor plus everolimus Phase III study on advanced breast cancer

Headache affects one of every two HIV/AIDS patients

Health Alliance, Bayer sign outcomes-based contract to support MS patients

FDA modifies requirements of Amgen's Nplate REMS Program

Headaches after TBI more prevalent among adolescents, girls

EnVivo presents positive EVP-6124 Phase 2b trial data on schizophrenia at 50th ACNP meeting

Converting patients to lamotrigine extended-release for epilepsy treatment found effective and safe

Study: 3D-TV may cause seizures in children and adolescents

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Baby boomers more likely to develop HCV

Einstein, Montefiore receive NINDS grant to establish clinical site for NeuroNEXT

ACGME approves Cedars-Sinai's neurology residency training program

Genentech announces results from pertuzumab studies on HER2-positive breast cancer

EC extends therapeutic indication for Soliris to treat atypical hemolytic uremic syndrome

Post traumatic stress disorder and concussion syndrome treatable three years after injury: Study

Suppressing mosquitoes - the only way of controlling dengue

Migraines and depression risk: Study finds link

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Headache News and Research

Latest Headache News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in